Drug intelligence / Profile preview

binafuxi

Development stage: Unknown
Lead developer: Xinjiang Yinduolan Pharmaceutical
Administration: Oral

Overview

Binafuxi is a traditional Uighur medicine (TUM) formulated as granules for the treatment of the common cold, specifically the heat syndrome (hot cold) variant. Developed by the Xinjiang Uygur Autonomous Region Institute of Drug Research and Xinjiang Yinduolan Pharmaceutical, it is derived from traditional medicinal plants, notably *Viola tianschanica* (known as Binafxi in Uighur). The drug has undergone Phase II and Phase III clinical trials in China to assess its efficacy in symptom resolution and safety profile.

Brand names: Binafuxi Granules
Other names: 比那甫西颗粒Binafxi Granules

Beyond the preview

Go deeper on binafuxi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on binafuxi.

Explore the full profile